ANI Pharmaceuticals reported third quarter 2026 net revenues of $290.8 million, up 27.6%, and GAAP diluted earnings per share of $1.51 versus $1.13 a year earlier. It cut its 2026 Cortrophin Gel revenue guidance to $480 million to $500 million from $520 million to $540 million, citing slower-than-expected conversion of demand into patients, while raising its adjusted EBITDA and adjusted EPS guidance, and it announced a recommended offer to acquire Egetis Therapeutics.
Q3 2026 Cortrophin Gel net revenues were $138.7 million, up 36.1%, while Brands revenue fell 6.5% to $10.0 million.
2026 Cortrophin Gel revenue guidance was revised to $480 million to $500 million, down from $520 million to $540 million; total company revenue guidance was narrowed to $1,085 million to $1,125 million.
Adjusted non-GAAP EBITDA guidance was raised to $290 million to $300 million, and adjusted non-GAAP diluted EPS guidance was raised to $9.37 to $9.71.
The Egetis offer is SEK 11.25 per share, valued at approximately $560 million including incentive programs; the acceptance period is expected to run from about November 20, 2026 to December 18, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From ANI Pharmaceuticals, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$883.37M
+43.8%
$3.32
—
8.9%
FY2024
$614.38M
+26.2%
$-1.04
-222.4%
-3.0%
FY2023
$486.82M
+53.9%
$0.85
—
3.9%
FY2022
$316.38M
+46.4%
$-3.05
—
-15.1%
FY2021
$216.14M
+3.7%
$-3.40
—
-19.7%
Frequently asked questions
When is ANI Pharmaceuticals's next earnings date?
ANI Pharmaceuticals has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did ANI Pharmaceuticals earn last quarter?
For the quarter ended Sep 2026, ANI Pharmaceuticals reported diluted EPS of $1.51 (+33.6% year over year) on revenue of $290.78M (+27.6%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.